2006, Number S2
PDF size: 344.83 Kb.
ABSTRACTThe classical pathophysiologic concept of the acute coronary syndromes is the coronary artery thrombosis as a consequence of rupture or vulnerable atherosclerotic plaques. Actually, it is also been considered that systemic inflammatory phenomenon play a central role in the plaque instability associated to the atherothrombotic activity of the tissue factor (TF). The thrombotic phenomenon is controlled by tissue factor, stimulating the way of the protease’s active receptors (PAR) and cause a negative cycle between inflammation and coagulation.
FUSTER V, BADIMON JJ, BADIMON L: Clinical-pathological correlations of coronary disease progression and regression. Circulation 1992; 86: III-1-III-11.
BADIMON JJ, ZAMAN A, HELFT G, ET AL: Acute coronary syndromes: pathophysiology and preventive priorities. Thromb Haemost 1999; 82: 997-1004.
FUSTER V, BADIMON JJ, CHESEBRO JH: Atherothrombosis: mechanisms and clinical therapeutic approaches. Vasc Med 1998; 3: 231-239.
FUSTER V, FAYAD ZA, BADIMON JJ. Acute coronary syndromes: biology. Lancet 1999; 353(Suppl 2): SII5-SII9.
FERNANDEZ-ORTIZ A, BADIMON JJ, FALK E ET AL: Characterization of the relative thrombogenicity of atherosclerotic plaque components: implications for consequences of plaque rupture. J Am Coll Cardiol 1994; 23: 1562-1569.
TOSCHI V, GALLO R, LETTINO M, FALLON JT, FERNANDEZ-ORTIZ A, BADIMON L, ET AL. Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. Circulation 1997; 95: 594-599.
LEVI M, TEN CATE H, BAUER KA, ET AL: Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees. J Clin Invest 1994; 93: 114-120.
PIXLEY RA, DE LC, PAGE JD, ET AL: The contact system contributes to hypotension but not disseminated intravascular coagulation in lethal bacteremia: in vivo use of a monoclonal anti-factor XII antibody to block contact activation in baboons. J Clin Invest 1993; 91: 61-68
RUF W, EDGINGTON TS: Structural biology of tissue factor, the initiator of thrombogenesis in vivo. FASEB J 1994; 8: 385-390.
TEDGUI A, MALLAT Z: Apoptosis as a determinant of atherothrombosis. Thromb Haemost 2001; 86: 420-426.
CAI W, DEVAUX B, SCHAPER W, ET AL: The role of Fas/APO 1 and apoptosis in the development of human atherosclerotic lesions. Atherosclerosis 1997; 131: 177-186.
FADOK VA, BRATTON DL, FRASCH SC, ET AL: The role of phosphatidylserine in recognition of apoptotic cells by phagocytes. Cell Death Differ 1998; 5: 551–562.
MALLAT Z, TEDGUI A: Current perspective on the role apoptosis in atherotrombotic disease. Circ Res 2001; 88: 998-1003.
MALLAT Z, HUGEL B, OHAN J, ET AL: Shed membrane microparticles with procoagulant potential in human atherosclerotic plaques: a role for apoptosis in plaque thrombogenicity. Circulation 1999; 99: 348-353.
LEVI M, VAN DER POLL T, BULLER HR: Bidirectional relation between inflammation and coagulation. Circulation 2004; 109: 2698-2704.
Coughlin SR, Camerer E: Participation in inflammation. J Clin Invest 2003; 111: 25-27.
COUGHLIN SR. Thrombin signaling and proteases-activated. Nature 2000; 407: 258-264.
SAMBRANO GR, WEISS EJ, ZHENG YW, ET AL: Role of thrombin signalling in platelets in haemostasis and thrombosis. Nature 2001; 413: 74-78.
MARUTSUKA K, HATAKEYAMA K, SATO Y, ET AL: Protease-activated receptor 2 (PAR2) mediates vascular smooth muscle cell migration induced by tissue factor/factor VIIa complex. Thromb Res 2002; 107: 271-276.
GEROTZIAFAS G, ZAFIROPOULOS A, VAN DREDEN P, ET AL: Inhibition of factor VIIa generation and prothrombin activation by treatment with enoxaparin in patients with unstable. Br J Haematol 2003; 120: 611-617.
KEATING FK, HAROLD HL, WHITAKER DA, SOBEL BE, SCHNEIDER DJ: The effects of bivalirudin compared with those of unfractionated heparin plus eptifibatide on inflammation and thrombin generation and activity during coronary intervention. Coron Artery Dis 2005; 16: 401-405.